SNGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Soligenix Inc (SNGX) is not a strong buy for a beginner investor with a long-term focus at this time. While there are positive developments in clinical trials and regulatory progress, the company's financial performance remains weak, and there are no strong technical or proprietary trading signals indicating a compelling entry point.
The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral at 55.04, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downtrend. Key resistance levels are at 1.193 and 1.236, with support at 1.056 and 1.013.
SGX945 received a positive EMA recommendation for Orphan Drug status, providing a 10-year market exclusivity.
Positive Phase 2a trial results for SGX945, showing a 40% improvement in Behçet's Disease patients.
Advancements in HyBryte™ (SGX
Phase 3 trials and strong intellectual property portfolio.
Development of vaccines like RiVax® supported by government grants, enhancing the company's position in the biodefense sector.
Regulatory challenges from the FDA and EMA could delay product development and approvals.
Weak financial performance with negative net income (-$2.53M) and declining EPS (-25.64% YoY).
No significant insider or hedge fund trading activity, indicating a lack of strong institutional interest.
In Q3 2025, revenue remained at $0 with no growth. Net income improved by 47.20% YoY but remains negative at -$2.53M. EPS declined by -25.64% YoY to -0.58. Gross margin remains at 0, indicating no profitability.
No data available for analyst ratings or price target changes.
